This is in contrast to the generally low incidence of VMA release in wet AMD patients and the negative effect of VMA at baseline on response to anti-VEGF agents, albeit mainly on the need for and frequency of repeat injections [23–25]. Here, VEGFA is linked to wet macular degeneration.